Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients

Murai, Jun; Soga, Sumiko; Saitō, Hiroshi; Otsuki, Michio; Kitada, Takanori; Saisho, Yoshifumi; Nakamura, Hitomi; Kasayama, Soji; Koga, Masafumi

doi:10.1507/endocrj.ej12-0364

Cited by 40 publications

(33 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study provides clinical evidence that improved glucose control after RYGB is an important regulator of serum levels of CA19-9 in patients with obesity and type 2 diabetes. Consistent with the current findings, Murai et al 21 reported that the serum levels of CA19-9 in six diabetic patients with markedly elevated CA19-9 levels decreased in conjunction with HbA1c after treatment with sulfonylureas or insulin. Additionally, Benhamou et al 7 showed that in patients having the worst metabolic control (ketoacidosis and hyperglycemic coma), CA 19-9 levels decreased after successful metabolic control.…”

Section: Discussionsupporting

confidence: 91%

“…Furthermore, BMI, TC, TG, LDL‐c, FPG, 2hPG, HbA1c, GA, and the HOMA‐IR index changed rapidly, progressively and significantly 12 weeks after RYGB in a cohort of patients diagnosed with obesity and type 2 diabetes. In accordance with this finding, the clinical and laboratory manifestations of type 2 diabetes are resolved or improved in the greater majority of patients after bariatric surgery Serum levels of CA19‐9 decreased markedly and significantly 12 weeks after RYGB, similar to the patients treated with sulfonylureas or insulin.…”

Section: Discussionsupporting

confidence: 70%

See 1 more Smart Citation

Decreased serum CA19‐9 is associated with improvement of insulin resistance and metabolic control in patients with obesity and type 2 diabetes after Roux‐en‐Y gastric bypass

Zhang

et al. 2014

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/IntroductionPatients with type 2 diabetes are known to show elevated serum levels of carbohydrate antigen 19-9 (CA19-9). The aim of the present study was to investigate the possible relationships of CA19-9 with metabolic control, insulin resistance (IR), and pancreatic β-cell function in patients with obesity and type 2 diabetes who underwent Roux-En-Y gastric bypass (RYGB).Materials and MethodsThe present study included 81 healthy volunteers, and 33 patients diagnosed with obesity and type 2 diabetes who underwent RYGB. Anthropometry, serum levels of CA19-9, glucose and lipid metabolic profiles, and serum insulin levels were determined at baseline and at 12 weeks after RYGB.ResultsChanges in CA19-9 were significantly and positively correlated with changes in fasting plasma glucose (r = 0.552, P = 0.001), 2-h post-challenge plasma glucose levels (r = 0.623, P = 0.000), glycated hemoglobin levels (r = 0.819, P = 0.000), glycated albumin levels (r = 0.711, P = 0.000), total cholesterol (r = 0.449, P = 0.009) and the Homeostasis Model of Assessment-IR index (r = 0.407, P = 0.019). Furthermore, a multiple stepwise regression analysis showed that the changes in serum levels of CA19-9 were independently and significantly associated with changes in glycated hemoglobin (β = 0.598, P = 0.000), fasting plasma glucose (β = 0.309, P = 0.000) and Homeostasis Model of Assessment-IR (β = 0.235, P = 0.010) after adjusting for confounding factors.ConclusionsCA19-9 could be an effective indicator of IR, and glycemic and lipid metabolism in patients with obesity and type 2 diabetes after rapid metabolic control by RYGB. Additionally, CA19-9 might be a marker with which to evaluate the short-term effects of glycolipid toxicity on IR in these patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 70%

Decreased serum CA19‐9 is associated with improvement of insulin resistance and metabolic control in patients with obesity and type 2 diabetes after Roux‐en‐Y gastric bypass

Zhang

et al. 2014

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…The pathology mechanism of this condition is that recurring metabolic disorders lead to chronic inflammation of the pancreas and a part of epithelial cells in the pancreatic are replaced by fat cells or fibrous connective tissue, and amyloid deposits might cause hyaline change in islets cells, which result in excessive secretion of serum CA 19-9 [17]. Meanwhile, Jun Murai, et al assumed that the serum CA 19-9 levels of patients with diabetes are elevated because half-life of serum CA 19-9 in diabetic patients might be apparently prolonged and catabolism of serum CA19-9 might be decreased [18]. Kamile Gul, et al suggested a new cutoff value for CA19-9 levels in T2DM, which is 57.14 U/ml at 97th percentile [2].…”

Section: Discussionmentioning

confidence: 99%

Serum CA 19–9 Level is Correlated to the Clinical Characteristics and Chronic Complications of Patients Newly Diagnosed with Type 2 Diabetes Mellitus

Cui

et al. 2019

Exp Clin Endocrinol Diabetes.

View full text Add to dashboard Cite

Aim This study investigated the relation of serum carbohydrate antigen 199 (CA 19–9) levels to the clinical characteristics and chronic complications of patients newly diagnosed with type 2 diabetes mellitus (T2DM). Methods A total of 371 patients newly diagnosed with T2DM and 133 healthy people with consecutively matched age were compared. The 371 patients with T2DM were divided into four groups by quartiles based on their serum CA 19–9 levels, in which clinical characteristics and chronic complications, such as diabetic retinopathy (DR), diabetic nephropathy, and macrovascular complications were compared. Logistic regression analysis was used to evaluate the risk factors of DR. Results Among the 371 patients newly diagnosed with T2DM, 60 had elevated CA 19–9 levels (16.17%). The frequencies of elevated serum CA 19–9 were 24.39% (30 of 123) for females and 12.10% (30 of 248) for males, in which the values for females were higher than those for males (P<0.01).Differences were observed among the serum CA 19–9 levels, hemoglobin A1c (HbA1c), and DR (P<0.05). Logistic regression analysis showed that serum CA 19–9 levels, fasting blood glucose (FBG) and fasting C-peptide (FC-P) were risk factors for DR (P<0.05). Conclusions Serum CA 19–9 levels were correlated with HbA1c and DR in patients newly diagnosed with T2DM. The elevated serum CA 19–9 levels, high FC-P, and FBG levels were important risk factors for DR in patients newly diagnosed with T2DM.

show abstract

“…Carbohydrate antigen (CA) 19‐9 is a tumor ‐related antigen that is primarily secreted by human pancreatic and biliary ductal cells, colon and gastric epithelia, and endometrial and salivary epithelia . Previous studies found that CA 19‐9 is intimately associated with glucose metabolism and pancreatic inflammation . One study found that serum CA 19‐9 is positively correlated with plasma total cholesterol (TC) levels .…”

Section: Introductionmentioning

confidence: 99%

“…3,4 Previous studies found that CA 19-9 is intimately associated with glucose metabolism and pancreatic inflammation. [5][6][7][8][9][10][11][12] One study found that serum CA 19-9 is positively correlated with plasma total cholesterol (TC) levels. 11 Given that both abnormal glucose metabolism and dyslipidemia play important roles in the pathogenesis of metabolic syndrome and data on the association between serum CA 19-9 and metabolic syndrome are limited, the aim of the present study was to investigate the relationship between serum CA 19-9 levels and metabolic syndrome.…”

Section: Introductionmentioning

confidence: 99%

Association between serum CA 19‐9 and metabolic syndrome: A cross‐sectional study

Cheng

Lin

et al. 2017

Journal of Diabetes

View full text Add to dashboard Cite

show abstract

Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients

Cited by 40 publications

References 23 publications

Decreased serum CA19‐9 is associated with improvement of insulin resistance and metabolic control in patients with obesity and type 2 diabetes after Roux‐en‐Y gastric bypass

Decreased serum CA19‐9 is associated with improvement of insulin resistance and metabolic control in patients with obesity and type 2 diabetes after Roux‐en‐Y gastric bypass

Serum CA 19–9 Level is Correlated to the Clinical Characteristics and Chronic Complications of Patients Newly Diagnosed with Type 2 Diabetes Mellitus

Association between serum CA 19‐9 and metabolic syndrome: A cross‐sectional study

Contact Info

Product

Resources

About